Jonathan Emord, Republican Candidate for U.S. Senate, Endorses Donald J. Trump for President of the United States
CLIFTON, Va., Dec. 6, 2023 /PRNewswire/ — Jonathan Emord, Republican candidate for U.S. Senate and constitutional litigator dubbed the “FDA Dragon Slayer”, has announced his endorsement of Donald J. Trump for President. Emord’s endorsement unites two influential figures in A
The Best Cruise Lines of 2023 for UK Travellers, According to Cruise Critic
P&O Cruises’ Arvia named ‘Best New Ship’, Silversea Cruises awarded ‘Best Luxury Cruise Line’, Scenic Eclipse II receives ‘Best New Expedition Ship’ and Viking Cruises named ‘Best River Cruise Line’ LONDON, Dec. 6, 2023 /PRNewswire/ — C
Global Crew Management Systems Strategic Report 2023: Market to Reach $4.9 Billion by 2030 – Growth in Construction of Smart Airports Emphasizes the Need for Crew Management
DUBLIN, Dec. 6, 2023 /PRNewswire/ — The “Crew Management Systems – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. Global Crew Management Systems Market to Reach $4.9 Billion by 2030 The global market for Crew Management Sy
Anesthesia Disposables Global Market Report 2024-2033
DUBLIN, Dec. 6, 2023 /PRNewswire/ — The “Anesthesia Disposables Global Market Report 2024” report has been added to ResearchAndMarkets.com’s offering. Global Anesthesia Disposables Market Reflects a Robust Growth Trajectory with Emphasis on Patient Safety and Infection Preve
Beond Holding Successfully Closes US$13M Pre-Series A Funding Round; Opens $25M Series A Round
The world’s first premium leisure airline continues successful fundraising following its oversubscribed $17M seed round in August 2023 DUBAI, UAE, Dec. 6, 2023 /PRNewswire/ — Beond, the world’s first premium leisure airline, is pleased to announce the successful completion of a US$
Perkbox announces new CEO as it supercharges its response to the cost-of-living crisis
LONDON, Dec. 6, 2023 /PRNewswire/ — Perkbox, the largest independent UK perks and benefits provider, has appointed Doug Butler as CEO. With extensive financial and operational expertise, Butler will be charged with driving continued global growth, overseeing product innovation and ensuring con
Koselugo now available in Malaysia for paediatric patients with symptomatic neurofibromatosis type 1 (NF1) plexiform neurofibromas
KUALA LUMPUR, Malaysia, Dec. 6, 2023 /PRNewswire/ — AstraZeneca’s Koselugo (selumetinib) is now available in Malaysia as a monotherapy for the treatment of paediatric patients three years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neur
Qilu Pharmaceutical Announces Results from Phase II Study for iparomlimab for Advanced Solid Tumors at ESMO Asia, with an ORR of 45.8%
JINAN, China, Dec. 6, 2023 /PRNewswire/ — Qilu Pharmaceutical presented the latest results of the single-arm, phase II pivotal clinical study for iparomlimab (QL1604), an innovative Class 1 antibody monotherapy used to treat unresectable or metastatic dMMR/MSI-H solid tumors through a poster p
Abzena Partners with ProteoNic to Offer Enhanced CHO Cell Line Platform for Complex Biologics
Premium vector technology will improve the production of high-yielding mammalian cell lines SAN DIEGO, Dec. 6, 2023 /PRNewswire/ — Abzena, the leading end-to-end bioconjugate and complex biologics CDMO has announced a partnership with ProteoNic Biosciences BV, to license their premium protein
Antengene Announces XPOVIO® Regulatory Approval in Macau for the Treatment of Relapsed and/or Refractory Multiple Myeloma
XPOVIO® (selinexor) is the first and only exportin 1 (XPO1) inhibitor approved in Macau. XPOVIO® has received regulatory approvals in 42 countries and regions including Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore and Australia. SHANGHAI AND HONG KONG, D